Xilio Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Xilio Therapeutics Inc
TickerXLO
CIK #0001840233
CUSIP98422T100
SectorLife Sciences - Pharmaceutical Preparations
Address828 Winter Street, Waltham, MA 02451
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Xilio Therapeutics Inc 2021-02-26 95.0 M Exemption: 506(b) · Duration: One year or less · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001840233] 10-K
[0001840233] 10-Q
[0001840233] 3
[0001840233] 4
[0001840233] 8-K
[0001840233] D
[0001840233] SC 13D
[0001840233] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Sirenia Capital Management LP Xilio Therapeutics Inc [2026-05-15] 0.0
OrbiMed Advisors LLC Xilio Therapeutics Inc [2026-05-15] 0.0
Coastlands Capital LP Xilio Therapeutics Inc [2025-12-11] 0.0
Stempoint Capital LP Xilio Therapeutics Inc [2025-11-14] 0.0
Point72 Asset Management LP Xilio Therapeutics Inc [2025-06-17] 0.0
Frazier Life Sciences Public Fund LP Xilio Therapeutics Inc [2025-06-12] 0.0
AbbVie Inc Xilio Therapeutics Inc [2025-02-18] 0.0
GKCC LLC Xilio Therapeutics Inc [2024-09-27] 15.9
Gilead Sciences Inc Xilio Therapeutics Inc [2024-04-05] 819419.9
Rock Springs Capital Management LP Xilio Therapeutics Inc [2024-02-14] 5.23
MRL Ventures Fund LLC Xilio Therapeutics Inc [2023-04-10] 5.4
Octagon Capital Advisors LP Xilio Therapeutics Inc [2023-01-25] 8.83
Takeda Pharmaceutical Co Ltd Xilio Therapeutics Inc [2022-01-14] 5.37
Bain Capital Life Sciences Fund II LP Xilio Therapeutics Inc [2021-11-05] 5.1
Rivervest Venture Fund IV LP Xilio Therapeutics Inc [2021-11-05] 5.4
RA Capital Management LP Xilio Therapeutics Inc [2021-11-05] 5.7
Atlas Venture Fund Xi LP Xilio Therapeutics Inc [2021-11-05] 7.6
FMR LLC Xilio Therapeutics Inc [2021-11-04] 0.0
SV7 Impact Medicine Fund LP Xilio Therapeutics Inc [2021-11-03] 6.05
Flynn James E Xilio Therapeutics Inc [2021-10-27] 4.29
Form 3/4/5 Filer 2011 - 2026
Bonstein Sara
Xilio Therapeutics Inc
Ross Robert W
Xu Yuan
Bello Akintunde Olatokumbo
Curran Daniel J
Shannon James Samuel
Brennan Aoife
Blanchard Cheryl R
Gilead Sciences Inc
Brennan Kevin M
Russo Rene
Frankenfield Christopher James
Luptakova Katarina
Rossi Christina
Clancy Paul J
Chudnovsky Yekaterina
GKCC LLC
Atlas Venture Fund XI LP
Atlas Venture Associates XI LP
Atlas Venture Associates XI LLC
Atlas Venture Opportunity Fund I LP
Atlas Venture Associates Opportunity I LLC
Atlas Venture Associates Opportunity I LP
Huber Martin H Jr
Heyman Tomas J
English Edward C
Ross Michael Jay
Giovine Salvatore
Bain Capital Life Sciences Investors II LLC
BCIP Life Sciences Associates LP
BCLS II Investco GP LLC
Bain Capital Life Sciences Fund II LP
Bain Capital Life Sciences Investors LLC
BCLS II Investco LP
FMR LLC
SV7 IMF GP LLP
SV7 Impact Medicine Fund LP
FIL Ltd
Deerfield Mgmt V LP
Deerfield Management Company LP
Deerfield Capital LP
Deerfield Partners LP
Flynn James E
RiverVest Venture Fund IV LP
Alexandria Venture Investments LLC
Takeda Pharmaceutical Co Ltd
Takeda Ventures Inc
Rock Springs Capital Master Fund LP
Rock Springs Capital Management LP
Four Pines Master Fund LP
Rock Springs Capital LLC
Merck KGaA
Bay City Capital LLC
Williams John Charles
Humphrey Rachel
Lynch Daniel
Estate of Ulrich Rodeck
Clackson Timothy P
Tomlinson Simon M
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Shannon James Samuel
Common Stock
2026-03-26 Buy 5,000 $8.79 43,950
Gilead Sciences Inc
Prefunded Warrants (right to buy) · derivative
2026-02-13 Buy 3,739,000 $0.53 1,981,670
Frankenfield Christopher James
Common Stock
2026-01-02 Sell 7,030 $0.64 4,499
Brennan Kevin M
Common Stock
2026-01-02 Sell 1,826 $0.64 1,169
Russo Rene
Common Stock
2026-01-01 Option exercise 44,250
Frankenfield Christopher James
Restricted Stock Units · derivative
2026-01-01 Option exercise 19,375 $0.00
Luptakova Katarina
Restricted Stock Units · derivative
2026-01-01 Option exercise 16,625 $0.00
Luptakova Katarina
Common Stock
2026-01-01 Option exercise 16,625
Russo Rene
Restricted Stock Units · derivative
2026-01-01 Option exercise 44,250 $0.00
Brennan Kevin M
Restricted Stock Units · derivative
2026-01-01 Option exercise 5,000 $0.00
Brennan Kevin M
Common Stock
2026-01-01 Option exercise 5,000
Frankenfield Christopher James
Common Stock
2026-01-01 Option exercise 19,375
Luptakova Katarina
Stock Option (right to buy) · derivative
2025-12-31 Grant 451,885 $0.00
Brennan Kevin M
Stock Option (right to buy) · derivative
2025-12-31 Grant 95,221 $0.00
Frankenfield Christopher James
Stock Option (right to buy) · derivative
2025-12-31 Grant 668,789 $0.00
Russo Rene
Stock Option (right to buy) · derivative
2025-12-31 Grant 1,500,258 $0.00
Gilead Sciences Inc
Series B Warrants (right to buy) · derivative
2025-11-26 Option exercise 13,335,000 $0.00
Gilead Sciences Inc
Prefunded Warrants (right to buy) · derivative
2025-11-26 Option exercise 13,335,000 $0.75 10,001,250
Frankenfield Christopher James
Stock Option (right to buy) · derivative
2025-11-21 Disposed to issuer 45,000
Frankenfield Christopher James
Stock Option (right to buy) · derivative
2025-11-21 Grant 23,786
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 24 2,619,481
2025-12-31 37 39,727,815
2025-09-30 36 22,051,916
2025-06-30 35 23,770,263
2025-03-31 36 22,528,206
2024-12-31 36 25,855,355
2024-09-30 34 15,953,020
2024-06-30 33 14,509,248
2024-03-31 32 12,890,249
2023-12-31 35 16,556,871
2023-09-30 32 15,860,510
2023-06-30 33 16,002,286
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com